.png)
SummaryThe Gelbe Liste and Rote Liste are the drug directories most German professionals grew up with. Each is a respected single reference. The practical question for a hospital pharmacy or a clinical team is not which of the two is better, but whether one directory is still enough when the daily work needs consolidation, interaction checking and international data at once. This guide shows where the single directory stops and compares it, by system class, with a consolidated platform. It is written for professionals, not patients.
The Gelbe Liste Pharmindex, from Vidal MMI, and the Rote Liste are curated directories of medicinal products marketed in Germany. They are strong at what they do: a reliable, structured reference for a single product. The Rote Liste holds short information derived from product information, not the full Fachinformationen (SmPCs). Where they stop is breadth: one directory is one source, focused on Germany, with interaction checking and international equivalents either limited or absent.
Three gaps recur in clinical practice. First, consolidation: a question about a product often also touches its price, availability, alternatives and interactions, which sit in separate sources. Second, medication safety: an interaction or contraindication check should run in the same step, not in a separate tool. Third, international data: shortages and specialty sourcing increasingly need the equivalent product in another country. A single national directory answers the first question well and the other three poorly.
A consolidated platform runs one query across many sources at once. pharmazie.com is the consolidated pharmaceutical data platform by DACON Datenbank Consulting GmbH that bundles 25+ specialist databases into a single search, exclusively for healthcare professionals. Instead of opening a directory, then a price source, then an interaction tool, a professional reaches a result in 2 to 5 clicks that would otherwise require 3 to 4 separate systems. The directory becomes one layer of a wider search rather than the whole answer.
Medication safety is where consolidation earns its place clinically. pharmazie.com includes the C.A.V.E. module for patient-individual risk checks (age, contraindications, allergies) and the ABDA interaction database for drug-drug interactions, both within the same search. That means a professional can move from identifying a product to checking its safety without switching tools. Our guide to an drug database with an interaction check covers the mechanics.
A Germany-only directory cannot answer a cross-border question. pharmazie.com carries product data across 50+ countries and 120,000+ international trade products, so when a product is short or unavailable, the equivalent in another market is in the same search. For clinical and procurement teams handling shortages, that international layer is often the deciding difference between a directory and a platform.
The three are different classes of tool, so the fair comparison is by class, not feature by feature.
| Criterion | Single directory (brand) | Product-information portal | Consolidated platform |
|---|---|---|---|
| Scope / sources | one source | product-information set | 25+ databases |
| Interaction check / AMTS | limited | partial | C.A.V.E. + ABDA interactions |
| International data | DE focus | DE focus | 50+ countries |
| PZN / active-ingredient search | yes | yes | yes, consolidated |
| Access | web / print | web | web + API |
| Best-fit audience | clinic, practice | professionals | trade, hospital, industry |
Hospital pharmacies gain most from the interaction and shortage layers together. Clinical teams benefit from a safety check in the same step as identification. Manufacturers and market-access teams value the international data and the API. A single directory remains perfectly good for a quick product look-up; the case for a platform is strongest wherever the next question after “what is this product” is “is it safe, is it available, and what is the equivalent”. For the wider landscape, see our comparison of German drug databases.
The Gelbe Liste and Rote Liste are strong single references, and this is not a case against them. It is a case for asking whether one directory still covers the daily work. Where consolidation, integrated interaction checking and international data matter, a platform that searches 25+ databases at once, with C.A.V.E. and ABDA interactions and product data across 50+ countries, is the professional-grade upgrade. The clearest way to judge the fit is a short demo.
Further reading: German drug databases compared · The ABDA database
